Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Advertisement: partnersand mid banner
Advertisement: Cambridge Network mid banner
Advertisement: CJBS mid banner
Advertisement: Excalibur Healthcare mid banner
Mid banner advertisement: BDO
Advertisement: EBCam mid banner
Advertisement: RSM mid banner
Advertisement: Mogrify mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement mid banner S-Tech 1
ARM Innovation Hub
29 September, 2021 - 22:35 By Tony Quested

Majestic Mestag seeking fresh talent

Cambridge-based Mestag Therapeutics, a breakthrough inflammatory disease and immuno-oncology company, is scaling fast and is keen to hire a large number of new recruits across a range of disciplines.

The company, which has already acquired a global reputation, wants a drug discovery project manager, several scientists and bioinformaticians – among other personnel.

If you want reasons to get out of bed for quality, game-changing work, then Mestag has fashioned a fabulous environment – and its science is recognised via a number of notable accolades.

The company has won Business Weekly’s Young Company of the Year Award against the strongest competition we have seen in 31 years of the competition (see page 11). 

Also this week, Fierce Biotech has named the company as one of 2021’s Fierce 15 biotechnology companies – designating it as one of the most promising early-stage biotech businessses in the industry. 

Susan Hill, the dynamic and globally renowned CEO of Mestag, said: “We are thrilled to be named among the industry’s most promising new biotech companies.

“At Mestag we are pioneering new therapeutic advances through our unique understanding of fibroblast populations, and the roles they play in influencing immune effector cells in disease.

“The talented and growing team at Mestag is making rapid strides in developing our platform and building a pipeline of new medicines to address a range of cancers and inflammatory diseases. 

“It is a tremendous honour that our approach and our team have been recognised with this Fierce 15 award.” 

Mestag’s mission is to develop impactful new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. 

Powerful new technologies enable diseased tissues to be analysed at a single-cell level and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as immune sentinels in perpetuating, and progressing disease.

Mestag is progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and cancer.

This is a fabulously led business. Susan Hill joined Mestag from Gyroscope Therapeutics where she served as chief business officer and helped drive the company’s $62 million Series B.

She was previously founding CEO of Orbit Biomedical ($12m Series A) and CBO of Freeline Therapeutics. Previously, Susan served in the Business & Corporate Development team at Alexion (ALXN) and during an eight-year tenure at Merck Serono steered a series of roles. She has an MA and PhD from the University of Cambridge.

Mestag is partnered with world-leading investors and institutions, including SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV and Northpond Ventures.

• PHOTOGRAPH: The Mestag Therapeutics team celebrates its latest successes

Newsletter Subscription

Stay informed of the latest news and features